Shaaltiel Yoseph 4
4 · Protalix BioTherapeutics, Inc. · Filed Jun 23, 2010
Insider Transaction Report
Form 4
Shaaltiel Yoseph
DirectorExecutive VP, R&D
Transactions
- Sale
Common Stock
2010-06-21$7.00/sh−52,973$370,811→ 816,781 total
Footnotes (1)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.